 |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
|
|||||||
|
||||||||
|
|
|
|
|
|
|
|
|
|
Gateway® |
||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
 Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Location of features
attL1 site: 14-113
Kozak translation initiation site: 129-139
TagBFP-AS: 136-834
MCS: 835-900
attL2 site: 920-1019
Kanamycin resistance gene: 2244-3038
pUC origin of replication: 3623-4266
Notice to Purchaser:
Evrogen Fluorescent Protein Products (the Products) are intended for research use only. The Products are covered by Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
Invitrogen Gateway® Technology: please see Limited Use Label License No. 19: Gateway® Cloning Products.
|
|
Copyright 2002-2011 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |